Breast Cancer Proteomics and Estrogen Receptor Status
Author Information
Author(s): Hans Neubauer, Clare Susan E, Wozny Wojciech, Schwall Gerhard P, Poznanović Slobodan, Stegmann Werner, Vogel Ulrich, Sotlar Karl, Wallwiener Diethelm, Kurek Raffael, Fehm Tanja, Cahill Michael A
Primary Institution: University of Tuebingen
Hypothesis
The study investigates the correlation between estrogen receptor status and the phosphorylation of PGRMC1 in breast cancer tumors.
Conclusion
PGRMC1 phosphorylation may be involved in the clinical differences that underpin breast tumors of differing estrogen receptor status.
Supporting Evidence
- Proteins significantly differentially abundant between estrogen receptor negative and positive tumors were consistent with published profiles.
- PGRMC1 was primarily expressed in ER-negative basal epithelial cells of mammary ductules.
- High levels of ER or PGRMC1 were almost mutually exclusive in individual cells.
- PGRMC1 phosphorylation status differed between ER-positive and ER-negative tumors.
Takeaway
The study found that a protein called PGRMC1 behaves differently in breast tumors depending on whether they have estrogen receptors, which could help explain why some tumors are harder to treat.
Methodology
The study analyzed whole tissue sections from 16 breast cancer tumors using multiplex imaging and two-dimensional PAGE gels to assess protein phosphorylation.
Potential Biases
Potential bias may arise from the selection of tumor samples and the methods used for protein analysis.
Limitations
The study's sample size is relatively small, which may limit the generalizability of the findings.
Participant Demographics
The study included 16 breast cancer patients, with 8 tumors being ER-positive and 8 being ER-negative.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website